Doug Janzen has been involved in the life sciences industry for the past 19 years. He is currently the founder and President of NorthView Ventures, an entity which invests in and provides strategic advisory services to a number of technology companies. Prior to that, he was President and CEO of Cardiome Pharma Corp., a NASDAQ-listed drug development company which raised over $300 million from investors and completed over $1 billion in licensing deals during his tenure. In 2010, Cardiome’s lead product BRINAVESS was approved and launched in Europe by Merck.
Prior to that, Doug was an investment banker with Cormark Securities, acting as managing director of life sciences. He is the past chairman of Life Sciences British Columbia, has served as a director of BioteCanada, and sits as a director on a number of public and private boards. Doug is a past winner of Vancouver’s Top 40 under 40 award, and is co-founder, President and Director of Aequus Pharmaceuticals, a company focused on the reformulation and novel delivery of approved therapeutics.